title: The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein.
abstract: The immunophilin family of proteins has a vast number of roles regulating a variety of biological processes through protein-protein interactions. A relatively new and divergent member of this family, FK506-binding protein like (FKBPL), is emerging as a key player in the DNA damage response, steroid receptor signalling and more recently, control of tumour growth where it regulates response to endocrine therapy in addition to acting as a novel antiangiogenic protein. As a new therapeutic peptide based on FKBPL approaches clinical trials, this article highlights a unique approach to targeting tumours that are resistant to current antiangiogenic therapies and supports the role of FKBPL as a novel prognostic and predictive biomarker, distinct from its other family members.
authors.affiliation: School of Pharmacy, Queen's University Belfast, UK.
authors.forename: Tracy
authors.initials: T
authors.lastname: Robson
authors.forename: Iain F
authors.initials: IF
authors.lastname: James
mesh_terms: D000595:Amino Acid Sequence; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D020104:Immunophilins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D022021:Tacrolimus Binding Proteins; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; C400101:FKBPL protein, human; D010446:Peptide Fragments; D022021:Tacrolimus Binding Proteins; D020104:Immunophilins